- Home
- CYRX vs MDWD Comparison
CYRX vs MDWD Comparison
Compare CYRX & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- MDWD
- Stock Information
- Founded
- CYRX 1999
- MDWD 2000
- Country
- CYRX United States
- MDWD Israel
- Employees
- CYRX N/A
- MDWD N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- CYRX Health Care
- MDWD Health Care
- Exchange
- CYRX Nasdaq
- MDWD Nasdaq
- Market Cap
- CYRX 277.5M
- MDWD 230.6M
- IPO Year
- CYRX N/A
- MDWD 2014
- Fundamental
- Price
- CYRX $6.37
- MDWD $19.09
- Analyst Decision
- CYRX Strong Buy
- MDWD Strong Buy
- Analyst Count
- CYRX 8
- MDWD 2
- Target Price
- CYRX $10.75
- MDWD $35.00
- AVG Volume (30 Days)
- CYRX 467.6K
- MDWD 59.0K
- Earning Date
- CYRX 08-05-2025
- MDWD 08-13-2025
- Dividend Yield
- CYRX N/A
- MDWD N/A
- EPS Growth
- CYRX N/A
- MDWD N/A
- EPS
- CYRX N/A
- MDWD N/A
- Revenue
- CYRX $232,134,000.00
- MDWD $19,213,000.00
- Revenue This Year
- CYRX N/A
- MDWD $20.80
- Revenue Next Year
- CYRX $9.63
- MDWD $26.92
- P/E Ratio
- CYRX N/A
- MDWD N/A
- Revenue Growth
- CYRX 11.75
- MDWD N/A
- 52 Week Low
- CYRX $4.58
- MDWD $12.78
- 52 Week High
- CYRX $9.93
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- CYRX 48.30
- MDWD 37.96
- Support Level
- CYRX $6.53
- MDWD $19.98
- Resistance Level
- CYRX $6.98
- MDWD $20.95
- Average True Range (ATR)
- CYRX 0.47
- MDWD 0.64
- MACD
- CYRX -0.01
- MDWD -0.38
- Stochastic Oscillator
- CYRX 56.38
- MDWD 0.29
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.